GSK PLC Sponsored ADR $GSK Stock Purchased by Mondrian Investment Partners LTD

Key Points

• Mondrian Investment Partners increased its GSK stake by 1.1%, adding 55,116 shares to own nearly 5 million shares valued at approximately $239.2 million. Institutional investors collectively own 15.74% of the company.
• Analyst sentiment remains mixed, with GSK carrying a consensus “Hold” rating and an average price target of $55.33; ratings include four Buys, twelve Holds and three Sells.
• GSK reported quarterly earnings and revenue above estimates, while raising its quarterly dividend to $0.4515 per share, equivalent to a 3.6% annualized yield.

Mondrian Investment Partners LTD increased its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 1.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,965,946 shares of the pharmaceutical company's stock after purchasing an additional 55,116 shares during the quarter. GSK accounts for 5.2% of Mondrian Investment Partners LTD's holdings, making the stock its 4th largest holding. Mondrian Investment Partners LTD owned about 0.25% of GSK worth $239,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of GSK. NewEdge Advisors LLC raised its position in GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company's stock valued at $49,986,000 after purchasing an additional 852,437 shares in the last quarter. Waverly Advisors LLC grew its position in shares of GSK by 1,372.8% during the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company's stock worth $15,233,000 after buying an additional 270,863 shares in the last quarter. Keystone Financial Planning Inc. grew its position in shares of GSK by 3,114.8% during the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company's stock worth $10,253,000 after buying an additional 189,506 shares in the last quarter. Kahn Brothers Group Inc. acquired a new position in shares of GSK during the second quarter worth about $8,305,000. Finally, Dorsey Wright & Associates acquired a new position in shares of GSK during the first quarter worth about $2,522,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wolfe Research started coverage on shares of GSK in a research note on Friday, October 9th. They set an "outperform" rating and a $70.00 target price on the stock. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Weiss Ratings cut shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, July 29th. Berenberg Bank reiterated a "buy" rating on shares of GSK in a report on Tuesday, October 6th. Finally, Citigroup began coverage on shares of GSK in a research report on Friday, July 24th. They issued a "neutral" rating on the stock. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $55.33.

GSK Stock Performance

NYSE:GSK opened at $50.74 on Friday. GSK PLC Sponsored ADR has a 12 month low of $42.85 and a 12 month high of $61.69. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm has a market capitalization of $102.64 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. The business's fifty day moving average price is $49.59 and its 200 day moving average price is $51.45.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%. GSK's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were given a dividend of $0.4515 per share. This is a boost from GSK's previous quarterly dividend of $0.44. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. GSK's dividend payout ratio is 55.31%.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.